Company: SRPT
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0000950170-25-064412
Chunk: 2

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part II, Item 1
Chunk 2
---
 products are prescribed by physicians, which depends on physicians’ views on the safety, effectiveness and efficacy of our products;

•our ability to secure and maintain adequate reimbursement for our products, including the duration of the prior-authorization as well as the number and duration of re-authorization processes required for patients who initially obtained coverage by third parties, including by government payors, managed care organizations and private health insurers;

•our ability to obtain and maintain patent protection for our products, to preserve our trade secrets, to prevent third parties from infringing on our proprietary rights and to operate without infringing on the proprietary rights of third parties;

•the development, commercialization or pricing of competing products or therapies for the treatment of Duchenne, or its symptoms, and the existence of competing clinical trials;

•our ability to increase awareness of the importance of genetic testing and knowing/understanding Duchenne mutations, and identifying and addressing procedural barriers to obtaining therapy;

•our ability to remain compliant with evolving laws and regulations that apply to us and our commercial activities;